Engflag

Rocklatan

Quick links to important sections

Rocklatan

Rocklatan_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rocklatan

Property Description
Active Ingredients Latanoprost, Netarsudil
Form Ophthalmic solution (Eye drops)
Pharmacological Class Dual Inhibitor (Rho kinase inhibitor and Prostaglandin F2alpha analog)
Common Purpose Reduction of elevated intraocular pressure (IOP)
Origin Synthetic Compounds

What Type of Medicine is ROCKLATAN?

ROCKLATAN is a prescription medication supplied as a sterile ophthalmic solution for topical use, formally classified as a fixed-dose combination product. This preparation is clinically recognized for integrating two distinct pharmacological agents into a single drop, a feature that distinguishes it from single-agent therapies. Pharmacologically, it is defined as a dual inhibitor, combining an agent from the established class of Prostaglandin F2alpha analogs with the distinct class of Rho kinase (ROCK) inhibitors. This two-in-one preparation provides a unique, targeted approach to pressure management.

Composition: Latanoprost and Netarsudil as a Fixed-Dose Combination

The two synthetically derived compounds that serve as the active ingredients are Latanoprost and Netarsudil. Latanoprost is categorized as a prodrug, becoming active after being absorbed by the eye, while Netarsudil represents the incorporation of a newer pharmacological mechanism specifically targeting the main fluid drainage structures. The fixed-dose combination design incorporates an intended synergistic effect. This combination provides the benefit of two complementary mechanisms in one medication, a key differentiating factor from other eye drops.

General Purpose and High-Level Action

The general purpose of ROCKLATAN is the efficient and sustained reduction of elevated intraocular pressure (IOP). The drug achieves this through the combined action of its components, which simultaneously increase the removal of aqueous humor from the eye via two separate drainage pathways. The dual mechanism actively supports outflow through the eye's primary drainage system, the trabecular meshwork (via Netarsudil), and enhances the secondary uveoscleral outflow (via Latanoprost). This comprehensive approach, combining two distinct pathways, is considered a therapeutic advancement for patients needing robust pressure control.

Regulatory References

  1. Netarsudil Ophthalmic: MedlinePlus Drug Information

What side effects are possible with Rocklatan?

Possible Side Effects and Safety Information

Rocklatan (netarsudil and latanoprost ophthalmic solution) may cause side effects, most of which are typically ocular and localized to the eye and surrounding area. The safety information below is based on data from controlled clinical studies and regulatory documents.

Common and Very Common Adverse Reactions

The most frequently observed adverse reactions, occurring in 10% or more of patients during clinical trials (classified as Very Common), were primarily eye-related:

  • Conjunctival Hyperemia (redness of the eye): Reported in 59% of patients, the most common side effect.
  • Instillation Site Pain (discomfort upon application): Reported in 20% of patients.
  • Corneal Verticillata (small, golden-brown or gray deposits on the outer surface of the eye): Reported in 15% of patients; generally mild and reversible upon discontinuation.
  • Conjunctival Hemorrhage (broken blood vessels on the white of the eye): Reported in 11% of patients.

Other less frequent common reactions (1% to 10%) include blurred vision, eye itching, and increased tear production.

Serious and Clinically Significant Safety Concerns

Regulatory warnings highlight the potential for serious or long-term effects:

  • Increased Pigmentation: The latanoprost component can cause an increase in brown pigment in the iris (colored part of the eye), which is likely to be permanent. It can also cause darkening of the periorbital tissue (eyelid skin) and increased length, thickness, and number of eyelashes, which are generally reversible upon stopping treatment.
  • Corneal Edema: Epithelial corneal edema has been reported, particularly in patients with pre-existing corneal issues or following certain eye procedures. This condition typically resolves after discontinuation.
  • Macular Edema: Macular edema, including cystoid macular edema, has been reported with latanoprost use. Caution is advised for patients who are aphakic, pseudophakic with a torn posterior lens capsule, or who have other known risk factors for macular edema.
  • Intraocular Inflammation: The drug should be used with caution in patients with a history of iritis/uveitis and should generally not be used in cases of active intraocular inflammation or active herpes simplex keratitis.
  • Bacterial Keratitis: Contamination of the multi-dose container may result in bacterial keratitis, which can cause serious eye damage and vision loss. The bottle tip should not touch the eye or surrounding structures.

Patients should remove contact lenses before administration and wait 15 minutes before reinserting them. If eye pain or decreased vision occurs, professional medical advice should be sought immediately.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Rocklatan

Overdose scope

Documented overdose presentations: – Acute signs following local overuse may include increased ocular irritation and the potential for a paradoxical increase in intraocular pressure (IOP). – Systemic overdose is characterized by the event of accidental ingestion of the ophthalmic solution.

Physiological systems affected (as stated in label): – Ocular system (irritation, redness). Systemic effects are not expected to be dangerous following accidental oral ingestion.

Dose-related or exposure-related factors (if applicable): – Using the medicine more than once daily is explicitly considered excessive and may lead to reduced efficacy.

Population-specific overdose notes (if applicable): – No specific information regarding altered overdose severity for any patient population is documented in the official labeling.

Emergency-response statements (as written in official documents): – Seek emergency medical attention immediately. – Call the Poison Help line at 1-800-222-1222.

When immediate medical help is required (label-derived phrasing only): – If anyone has accidentally swallowed the medication.

Overdose classifications (high-level)

Severity classification (as defined in official documents): – Accidental systemic overdose is officially classified as not expected to be dangerous.

Regulatory basis (EMA / FDA / etc.): – FDA Prescribing Information / EMA SmPC.

Overdose-context constraints (as defined in official documents): – Urgent medical response is specifically constrained to the event of accidental swallowing or ingestion.

Resulting overdose structure

Official overdose statements: • Regulatory labeling states that accidental systemic overdose is not expected to be dangerous. • The formal action required for accidental ingestion is to seek emergency medical attention or call the Poison Help line. • Topical overuse can be associated with documented effects such as conjunctival hyperaemia and potential for paradoxical elevations in IOP. • Management for overdose involves providing symptomatic and supportive treatment.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the official overdose profile by distinguishing between low-risk accidental systemic ingestion, which requires immediate contact with emergency services, and local ocular overuse. The documentation mandates that the dosage should not exceed the once-daily frequency to avoid documented effects, and confirms that management for any overdose situation is limited to supportive care.

Therapeutic Uses of Rocklatan

What Rocklatan Treats: Main Uses and Benefits

Rocklatan is commonly used to help with the management of pathologically elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension. The medicine is relevant in chronic conditions where the goal is the reduction of elevated IOP. This supports efforts in managing the primary risk factor for damage.

The medication is applied in clinical settings where chronic pressure management is required, often when a patient's existing single-agent therapy is considered relevant when additional support is needed to achieve desired pressure levels. This therapeutic domain is applicable within conditions presenting with systemic or localized discomfort. A key patient-oriented benefit is the support it provides in maintaining long-term visual function.

The primary indications the medication may assist with include: ocular hypertension, primary open-angle glaucoma, and situations when single-agent therapy is not sufficient to control pressure. In these scenarios, the combination treatment supports a stable reduction of IOP that helps patients cope more steadily with their condition.

“This dual-action approach assists with maintaining functional stability when additional pressure-lowering support is needed.”

Quick Fact: Symptom Management for Elevated IOP

Eligibility and Restrictions for Use

Rocklatan is indicated for use only in adult patients (aged 18 and older) with open-angle glaucoma or ocular hypertension. The safety and effectiveness of the medicine have not been established in the pediatric population (patients under 18 years of age) and it is therefore not approved for use in children or adolescents.

Contraindicated and Restricted Use

Use of Rocklatan is strictly contraindicated in patients with a known history of hypersensitivity (allergy) to netarsudil, latanoprost, or any other ingredient in the solution. This is the sole absolute contraindication listed in the official prescribing information.

Use is not recommended or requires caution in several other specific populations:

  • Active Ocular Inflammation: It should generally not be used in patients with active intraocular inflammation (such as iritis or uveitis) or active Herpes Simplex keratitis, as the condition may be exacerbated.
  • Pregnancy and Lactation: There is no adequate data on use during pregnancy, and the medicine is generally not recommended. For breastfeeding, the decision must be made to discontinue the drug or discontinue nursing.
  • Aphakia/Macular Edema Risk: Caution is advised for aphakic patients or those with risk factors for macular edema, due to reports associated with one of the components.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Rocklatan

Interaction scope

Item Statement Classification
Medicinal Product Categories Prostaglandin analogues, derivatives, or other topical ophthalmic products Pharmacodynamic and Timing
Specific Interacting Medicines No specific drug-to-drug names outside of the prostaglandin analogue class are listed in official regulatory labeling. Regulatory Basis
Mechanistic Basis Pharmacodynamic effects (IOP elevation) and Physical Incompatibility (precipitation). Netarsudil shows in vitro CYP450 inhibition without current clinical evidence. Pharmacodynamic and Pharmacokinetic
Timing-based Rules All other topical ophthalmic products must be administered at least five (5) minutes apart from this medicine. Administration Constraint
Population-specific Notes No specific drug-drug interaction cautions relevant to defined patient populations are documented. Regulatory Basis
Interaction-related Restrictions The co-administration of two or more prostaglandins, or prostaglandin analogues or derivatives, is not recommended. Formal Restriction

Interaction classifications (high-level)

Item Statement
Interaction Severity Classification The co-administration of prostaglandin analogues is subject to a formal "not recommended" restriction due to the risk of paradoxical Intraocular Pressure (IOP) elevation.
Regulatory Basis The documented interactions are based on assessments by the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), and other national health authorities.
Interaction-context Constraints Interactions are limited to topical ophthalmic use and theoretical local enzyme inhibition. Low systemic exposure suggests a low potential for systemic drug-drug interactions.

Resulting interaction structure

The regulatory interaction profile for this medicine is principally defined by pharmacodynamic constraints and mandatory timing rules for co-administering topical eye products. Co-administration with other prostaglandin analogues is not recommended due to the risk of a counteracting effect leading to paradoxical elevations in IOP. Furthermore, other topical ophthalmic medicinal products require a separation interval of at least five minutes to mitigate interference; this rule also applies to eye drops containing thiomersal due to an in vitro precipitation risk. The active components exhibit low systemic absorption, reducing the likelihood of systemic drug interactions.

Mechanism of Action

How Rocklatan Works

Rocklatan initiates two distinct, complementary mechanisms that focus on increasing the outflow of aqueous humor from the eye, modulating the resistance within the ocular fluid drainage system.

Enhanced Drainage by Modulating the Primary Outflow Filter

This domain is driven by Netarsudil, which acts as an inhibitor of the Rho Kinase (ROCK) enzyme in the cells of the trabecular meshwork (TM). By inhibiting ROCK, the natural contractile tension within the TM cells is reduced, which modulates the resistance to fluid flow and increases drainage through the eye's main filter.

Dual-Pathway Mechanism: Modulation of the Secondary Route

This domain is governed by Latanoprost, which acts as an agonist on the Prostaglandin F2alpha (FP) receptor. Receptor activation leads to the release of enzymes that remodel the connective tissue in the uveoscleral pathway, leading to increased permeability in this secondary drainage route. The simultaneous targeting of the TM and the uveoscleral pathway results in a dual-mechanism increase in overall fluid clearance.

Dosage and Administration Information

The administration of Rocklatan (netarsudil/latanoprost ophthalmic solution) involves specific procedures to ensure correct topical delivery to the eye.

Administration and Dosing Schedule

The recommended dosage is one drop in the affected eye(s) once daily in the evening. The drug should be applied into the conjunctival sac of the affected eye(s) and the dosage should not exceed once daily.

Administration Scope Instruction
Route of Administration Ophthalmic (topical to the eye)
Dosing Frequency Once daily
Timing In the evening
Maximum Dose Should not exceed once daily

Procedural and Co-administration Rules

To maintain the sterility of the solution, the tip of the dispensing container must avoid contacting the eye, surrounding structures, fingers, or any other surface. This is a crucial procedural step to minimize the risk of solution contamination.

If using other topical ophthalmic drug products, they must be administered at least five minutes apart from Rocklatan to prevent unintended interaction or washout. Soft contact lenses must be removed prior to instillation and may be reinserted 15 minutes after the administration of the eye drops.

If a dose is missed, treatment should simply continue with the next scheduled dose in the evening; do not double doses to make up for the missed application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rocklatan

Evidence for Use in Managing Elevated Intraocular Pressure

Rocklatan was studied for use in adult patients diagnosed with open-angle glaucoma or ocular hypertension, both conditions marked by functional limitations due to elevated eye pressure. The regulatory evidence base primarily consists of multiple large, randomized controlled trials (RCTs), which is the type of research designed to compare an investigational treatment against standardized control treatments.

These pivotal studies explored outcomes related to the change in eye pressure over defined time intervals. The trials were designed to evaluate the fixed-dose combination compared to its two separate components: Latanoprost monotherapy and Netarsudil monotherapy. The research included patients with elevated baseline eye pressure.

The findings describe patterns observed in the studies over the primary comparative period of 90 days. Research highlights changes measured during the study period in the intraocular pressure (IOP) of the observed adult populations. The combination was studied for use in participants presenting with elevated IOP.

Outcomes Measured in Core Clinical Trials

  • The main outcomes researchers studied for this medicine were related to a specific surrogate biomarker: the pressure inside the eye. The core clinical trials primarily monitored the change from baseline in mean diurnal Intraocular Pressure (IOP).
  • Additionally, the studies monitored the number of participants who were observed achieving a predefined target low IOP goal, typically set around 16 mmHg or lower. This specific goal is an outcome related to physiological strain or stress.

Evidence Gaps and Areas for Further Research

  • The clinical evidence landscape is characterized by its reliance on the measured change in IOP as a key parameter, which is considered a surrogate biomarker rather than a measure of a functional outcome. Long-term effects are not fully established regarding outcomes related to actual vision preservation or optic nerve health, as these outcomes were not the primary comparative measurements in the core registration studies.
  • Follow-up durations were limited when assessing the comparative effects over several years. Certainty remains low for many small subgroups, and the results apply only to the populations studied within the clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Rocklatan (FAQ)

Q: How quickly does Rocklatan typically start working and how long do the effects last after stopping?

Studies and official information indicate that the full pressure-lowering effect is observed over the primary clinical study period, typically within 90 days of consistent use. Regulatory documents state that upon stopping the medicine, the effect on eye pressure will decrease, and the pressure is expected to gradually return to the pre-treatment level.

Q: Why is Rocklatan often taken only once a day?

Official prescribing information indicates a recommended dosage of one drop in the affected eye(s) once daily in the evening. This specific frequency and timing are established based on the drug's properties and the results observed during clinical development, reflecting the drug’s intended duration of action demonstrated in clinical studies.

Q: Can Rocklatan be used by people with a history of heart, liver, or kidney problems?

Official prescribing documents do not specify dosage adjustments or offer explicit warnings regarding the use of this medicine for patients with pre-existing heart, liver, or kidney conditions. The active ingredients demonstrate very low systemic exposure (meaning minimal amounts enter the rest of the body) following topical administration. Regulatory documents do not address these specific conditions.

Q: Does Rocklatan interact with common vitamins, supplements, alcohol, or food?

Regulatory documents do not contain documented interactions between this medicine and common vitamins, supplements, alcohol, or food. The drug’s known interaction profile is primarily defined by the required separation interval for co-administering other topical eye products.

Q: What happens if Rocklatan gets into my mouth or nose?

This medicine is for ophthalmic (eye) use only. Official documents advise that if accidental ingestion or improper administration (such as getting it into the mouth or nose) occurs, patients should immediately contact a healthcare professional or Poison Control Center for guidance. Adherence to the correct administration instructions is intended to minimize the risk of misapplication.

Q: What are the ingredients in Rocklatan besides the main components?

The formulation contains the preservative benzalkonium chloride (BAC). According to the official description section, the solution also contains other inactive ingredients necessary for maintaining the solution's stability, tonicity, and pH balance.

How should Rocklatan be stored and disposed of?

How to Store and Dispose of Rocklatan?

This medication has specific storage requirements to maintain its stability and effectiveness, based on official regulatory labeling.

Storage Condition Unopened Bottle Opened Bottle (In-Use)
Temperature Refrigerate: 36 F to 46 F (2 C to 8 C) Store at 36 F to 77 F (2 C to 25 C) for up to 6 weeks, OR refrigerate until expiration date.
Light Protection Protect from light Protect from light

Handling Requirements:

  • Do not freeze this medication.
  • Keep the bottle tightly closed in its original container when not in use.
  • Keep the medicine and all containers out of the reach of children and pets.

Disposal: When the product is no longer needed or has expired, dispose of it safely. This helps prevent accidental consumption by others and protects the environment from harm.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Rocklatan found in:

A-Z Index: